Revision of MELD to Include Serum Albumin Improves Prediction of Mortality on the Liver Transplant Waiting List

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Myers, Robert P ^a   Shaheen, Abdel Aziz M ^a   Faris, Peter ^a   Aspinall, Alexander I ^a   Burak, Kelly W ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CORRELATION ANALYSIS; DEATH; FEMALE; HOSPITAL ADMISSION; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE; MORTALITY; PREDICTION; REGISTER; SCORING SYSTEM; SURVIVOR; UNITED STATES;

ADULT; END STAGE LIVER DISEASE; FEMALE; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, STATISTICAL; SERUM ALBUMIN; WAITING LISTS;

EID: 84872546335     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051926     Document Type: Article

References (44)

1. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, et al. (2000) A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 31: 864-871.
2. Freeman RB Jr, Wiesner RH, Harper A, McDiarmid SV, Lake J, et al. (2002) The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 8: 851-858.
3. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, et al. (2001) A model to predict survival in patients with end-stage liver disease. Hepatology 33: 464-470.
4. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, et al. (2003) Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 124: 91-96.
5. Kamath PS, Kim WR, (2007) The model for end-stage liver disease (MELD). Hepatology 45: 797-805.
6. McDiarmid SV, Anand R, Lindblad AS, (2002) Development of a pediatric end-stage liver disease score to predict poor outcome in children awaiting liver transplantation. Transplantation 74: 173-181.
7. Brown RS Jr, Lake JR, (2005) The survival impact of liver transplantation in the MELD era, and the future for organ allocation and distribution. Am J Transplant 5: 203-204.
8. Bambha KM, Biggins SW, (2008) Inequities of the Model for End-Stage Liver Disease: an examination of current components and future additions. Curr Opin Organ Transplant 13: 227-233.
9. Sharma P, Schaubel DE, Sima CS, Merion RM, Lok AS, (2008) Re-weighting the model for end-stage liver disease score components. Gastroenterology 135: 1575-1581.
10. Myers RP, Shaheen AA, Aspinall AI, Quinn RR, Burak KW, (2011) Gender, renal function, and outcomes on the liver transplant waiting list: Assessment of revised MELD including estimated glomerular filtration rate. J Hepatol 54: 462-470.
11. Tripodi A, Chantarangkul V, Primignani M, Fabris F, Dell'Era A, et al. (2007) The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology 46: 520-527.
12. Huo SC, Huo TI, Lin HC, Chi CW, Lee PC, et al. (2007) Is the corrected-creatinine model for end-stage liver disease a feasible strategy to adjust gender difference in organ allocation for liver transplantation? Transplantation 84: 1406-1412.
13. Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, et al. (2008) Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 359: 1018-1026.
14. Huo TI, Wang YW, Yang YY, Lin HC, Lee PC, et al. (2007) Model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor and its correlation with portal pressure in patients with liver cirrhosis. Liver Int 27: 498-506.
15. Therneau TM, Grambsch PM (2000) Modeling survival data: extending the Cox model. New York, NY: Springer-Verlag. 107-111 p.
16. D'Agostino RB, Nam BH (2004) Evaluation of the performance of survival analysis models: discrimination and calibration measures. In: Balakrishnan N, Rao CR, editors. Advances in survival analysis. Amsterdam: Elsevier. pp. 1-25.
17. Heagerty PJ, Zheng Y, (2005) Survival model predictive accuracy and ROC curves. Biometrics 61: 92-105.
18. Kremers WK Concordance for survival time data: Fixed and time-dependent covariates and possible ties in predictor and time. Technical Report Series #80, April 2007 (http://mayoresearch.mayo.edu/mayo/research/biostat/upload/80.pdf). Accessed November 1, 2009.
19. Janes H, Pepe MS, Gu W, (2008) Assessing the value of risk predictions by using risk stratification tables. Ann Intern Med 149: 751-760.
20. Cook NR, (2008) Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Clin Chem 54: 17-23.
21. Cook NR, Ridker PM, (2009) Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med 150: 795-802.
22. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS, (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27: 157-172; discussion 207-112.
23. Luca A, Angermayr B, Bertolini G, Koenig F, Vizzini G, et al. (2007) An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl 13: 1174-1180.
24. Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, et al. (2007) Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 298: 776-785.
25. Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, et al. (2008) Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med 148: 337-347.
26. Paynter NP, Chasman DI, Buring JE, Shiffman D, Cook NR, et al. (2009) Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med 150: 65-72.
27. Kathiresan S, Melander O, Anevski D, Guiducci C, Burtt NP, et al. (2008) Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 358: 1240-1249.
28. Meigs JB, Shrader P, Sullivan LM, McAteer JB, Fox CS, et al. (2008) Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 359: 2208-2219.
29. Zoli M, Cordiani MR, Marchesini G, Iervese T, Labate AM, et al. (1991) Prognostic indicators in compensated cirrhosis. Am J Gastroenterol 86: 1508-1513.
30. Merkel C, Bolognesi M, Angeli P, Noventa F, Caregaro L, et al. (1989) Prognostic indicators of survival in patients with cirrhosis and esophageal varices, without previous bleeding. Am J Gastroenterol 84: 717-722.
31. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, et al. (1997) Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112: 463-472.
32. Realdi G, Fattovich G, Hadziyannis S, Schalm SW, Almasio P, et al. (1994) Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 21: 656-666.
33. D'Amico G, Garcia-Tsao G, Pagliaro L, (2006) Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 44: 217-231.
34. Schaubel DE, Guidinger MK, Biggins SW, Kalbfleisch JD, Pomfret EA, et al. (2009) Survival benefit-based deceased-donor liver allocation. Am J Transplant 9: 970-981.
35. Vincent JL, Dubois MJ, Navickis RJ, Wilkes MM, (2003) Hypoalbuminemia in acute illness: is there a rationale for intervention? A meta-analysis of cohort studies and controlled trials. Ann Surg 237: 319-334.
36. Doumas BT, Peters T Jr, (1997) Serum and urine albumin: a progress report on their measurement and clinical significance. Clin Chim Acta 258: 3-20.
37. Doumas BT, Watson WA, Biggs HG, (1971) Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chim Acta 31: 87-96.
38. Doumas BT, Peters T Jr, (2009) Origins of dye-binding methods for measuring serum albumin. Clin Chem 55: 583-584.
39. College of American Pathologists. Surveys 2010 Clinical Chemistry. College of American Pathologists, Northfield, IL. 2010.
40. Maguire GA, Price CP, (1986) Bromcresol purple method for serum albumin gives falsely low values in patients with renal insufficiency. Clin Chim Acta 155: 83-87.
41. Bush V, Reed RG, (1987) Bromcresol purple dye-binding methods underestimate albumin that is carrying covalently bound bilirubin. Clin Chem 33: 821-823.
42. Cholongitas E, Marelli L, Kerry A, Senzolo M, Goodier DW, et al. (2007) Different methods of creatinine measurement significantly affect MELD scores. Liver Transpl 13: 523-529.
43. Trotter JF, Olson J, Lefkowitz J, Smith AD, Arjal R, et al. (2007) Changes in international normalized ratio (INR) and model for endstage liver disease (MELD) based on selection of clinical laboratory. Am J Transplant 7: 1624-1628.
44. Ravaioli M, Masetti M, Ridolfi L, Capelli M, Grazi GL, et al. (2007) Laboratory test variability and model for end-stage liver disease score calculation: effect on liver allocation and proposal for adjustment. Transplantation 83: 919-924.